Search

Your search keyword '"Tjwa, Eric"' showing total 254 results
Start Over Author "Tjwa, Eric"
254 results on '"Tjwa, Eric"'

2. Nationwide treatment and outcomes of intrahepatic cholangiocarcinoma

Author

Olthof, Pim B., Franssen, Stijn, van Keulen, Anne-Marleen, van der Geest, Lydia G., Hoogwater, Frederik J.H., Coenraad, Minneke, van Driel, Lydi M.J.W., Erdmann, Joris I., Mohammad, Nadia H., Heij, Lara, Klümpen, Heinz-Josef, Tjwa, Eric, Valkenburg-van Iersel, Liselot, Verheij, Joanne, and Koerkamp, Bas G.

Published
2023
Full Text
View/download PDF

3. Liver steatosis is prevalent in lean people living with HIV and associated with exposure to antiretroviral treatment – a cross-sectional study

Author

Van Eekeren, Louise E, primary, Vadaq, Nadira, additional, Vos, Wilhelm A J W, additional, Blaauw, Marc J T, additional, Groenendijk, Albert L, additional, Van Lunzen, Jan, additional, Stalenhoef, Janneke E, additional, Berrevoets, Marvin A H, additional, Verbon, Annelies, additional, Weijers, Gert, additional, Netea, Mihai G, additional, Van Der Ven, André J A M, additional, De Mast, Quirijn, additional, Joosten, Leo A B, additional, and Tjwa, Eric T T L, additional

Published
2024
Full Text
View/download PDF

4. Extensive splanchnic vein thrombosis after SARS-CoV-2 vaccination a Vascular Liver Disease Group (VALDIG) initiative

Author

Maan, Raoel, primary, Lauw, Mandy N., additional, China, Loise, additional, Patch, David, additional, Baiges, Anna, additional, Garcia-Pagan, Juan Carlos, additional, Hernández-Gea, Virginia, additional, Hilleret, Marie-Noelle, additional, Tjwa, Eric T., additional, Kounis, Ilias, additional, Bureau, Christophe, additional, Giguet, Baptiste, additional, Heurgué, Alexandra, additional, Ollivier-Hourmand, Isabelle, additional, Causse, Xavier, additional, Nery, Filipe, additional, Eshraghian, Ahad, additional, Plessier, Aurélie, additional, and Darwish Murad, Sarwa, additional

Published
2024
Full Text
View/download PDF

5. Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease

Author

Kocheise, Lorenz, primary, Piseddu, Ignazio, additional, Vonderlin, Joscha, additional, Tjwa, Eric T., additional, Buescher, Gustav, additional, Meunier, Lucy, additional, Goeggelmann, Pia, additional, Fianchi, Francesca, additional, Dumortier, Jérôme, additional, Barciela, Mar Riveiro, additional, Gevers, Tom J. G., additional, Beretta-Piccoli, Benedetta Terziroli, additional, Londoño, Maria-Carlota, additional, Frankova, Sona, additional, Roesner, Thomas, additional, Joerg, Vincent, additional, Schmidt, Constantin, additional, Glaser, Fabian, additional, Sutter, Jan P., additional, Fründt, Thorben W., additional, Lohse, Ansgar W., additional, Huber, Samuel, additional, von Felden, Johann, additional, Sebode, Marcial, additional, and Schulze, Kornelius, additional

Published
2024
Full Text
View/download PDF

6. PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease

Author

Kocheise, Lorenz, primary, Piseddu, Ignazio, additional, Vonderlin, Joscha, additional, Tjwa, Eric T., additional, Buescher, Gustav, additional, Meunier, Lucy, additional, Goeggelmann, Pia, additional, Fianchi, Francesca, additional, Dumortier, Jérôme, additional, Riveiro Barciela, Mar, additional, Gevers, Tom J. G., additional, Terziroli Beretta-Piccoli, Benedetta, additional, Londoño, Maria-Carlota, additional, Frankova, Sona, additional, Roesner, Thomas, additional, Joerg, Vincent, additional, Schmidt, Constantin, additional, Glaser, Fabian, additional, Sutter, Jan P., additional, Fründt, Thorben W., additional, Lohse, Ansgar W., additional, Huber, Samuel, additional, von Felden, Johann, additional, Sebode, Marcial, additional, and Schulze, Kornelius, additional

Published
2024
Full Text
View/download PDF

7. Liver Steatosis is Prevalent in Lean People With HIV and Associated With Exposure to Antiretroviral Treatment—A Cross-sectional Study.

Author

Eekeren, Louise E van, Vadaq, Nadira, Vos, Wilhelm A J W, Blaauw, Marc J T, Groenendijk, Albert L, Lunzen, Jan van, Stalenhoef, Janneke E, Berrevoets, Marvin A H, Verbon, Annelies, Weijers, Gert, Netea, Mihai G, Ven, André J A M van der, Mast, Quirijn de, Joosten, Leo A B, and Tjwa, Eric T T L

Subjects
ANTIRETROVIRAL agents, FATTY degeneration, HIV-positive persons, HEALTH facilities, HEPATIC fibrosis
Abstract

Background Steatotic liver disease is suggested to have a higher prevalence and severity in people with HIV (PHIV), including in those with a normal body mass index (BMI). In this study, we used data from the 2000HIV cohort to (1) assess the prevalence of liver steatosis and fibrosis in lean versus overweight/obese PHIV and (2) assess associations in these subgroups between steatosis and fibrosis with traditional risk factors and HIV-specific characteristics. Methods The 2000HIV study cohort comprises 1895 virally suppressed PHIV that were included between 2019 and 2021 in 4 HIV treatment centers in the Netherlands. The majority (58.5%) underwent vibration-controlled transient elastography for the assessment of liver steatosis and fibrosis. The prevalence of steatosis (controlled attenuation parameter ≥263 dB/m) and fibrosis (liver stiffness measurement ≥7.0 kPa) was estimated. Multiple factors including HIV characteristics and antiretroviral drugs were tested in a logistic regression model for association with steatosis and fibrosis. Analyses were performed separately for lean (Asian descent: BMI < 23 kg/m2, other descent: BMI < 25 kg/m2) and overweight/obese (other BMI) participants. Results Of 1050 PHIV including 505 lean and 545 overweight/obese PHIV, liver steatosis was observed in 37.7% of the overall study population, 19.7% of lean, and 54% of overweight/obese PHIV, whereas fibrosis was observed in 9.0% of the overall study population, 5.9% of lean, and 12.0% of overweight/obese PHIV. All associations with fibrosis and most associations with steatosis concerned metabolic factors such as type 2 diabetes mellitus (overall population: adjusted odds ratio [aOR] for steatosis: 2.3 [1.21-4.4], P =.011; aOR for fibrosis: 3.7 [1.82-7.53], P <.001). Furthermore, in lean PLHIV, liver steatosis was associated with CD4 and CD8 counts at enrollment, dual therapy, and history of treatment with raltegravir (aOR: 3.6 [1.53-8.47], P =.003), stavudine (aOR: 3.73 [1.69-8.2], P =.001), and indinavir (aOR: 3.86 [1.59-9.37], P =.003). These associations were not observed in overweight/obese PHIV. Conclusions Liver steatosis was highly prevalent, affecting approximately one-fifth of lean PHIV and half of overweight/obese PHIV. Fibrosis was observed in a minority. Both steatosis and fibrosis were associated with traditional metabolic risk factors. In addition, (prior) exposure to specific antiretroviral drugs was associated liver steatosis in lean, but not in overweight/obese PHIV. Implementing increased screening protocols could enhance the identification of steatotic liver disease in lean PHIV. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Transarterial Chemoembolization With Drug-Eluting Beads Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Outcomes From a Multicenter, Randomized, Phase 2 Trial (the TRENDY Trial)

Author

Méndez Romero, Alejandra, primary, van der Holt, Bronno, additional, Willemssen, Francois E.J.A., additional, de Man, Rob A., additional, Heijmen, Ben J.M., additional, Habraken, Steven, additional, Westerveld, Henrike, additional, van Delden, Otto M., additional, Klümpen, Heinz-Josef, additional, Tjwa, Eric T.T.L., additional, Braam, Pètra M., additional, Jenniskens, Sjoerd F.M., additional, Vanwolleghem, Thomas, additional, Weytjens, Reinhilde, additional, d'Archambeau, Olivier, additional, de Vos-Geelen, Judith, additional, Buijsen, Jeroen, additional, van der Leij, Christiaan, additional, den Toom, Wilhelm, additional, Sprengers, Dave, additional, IJzermans, Jan N.M., additional, and Moelker, Adriaan, additional

Published
2023
Full Text
View/download PDF

9. PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune liver disease

Author

Kocheise, Lorenz, primary, Piseddu, Ignazio, additional, Vonderlin, Joscha, additional, Tjwa, Eric T, additional, Buescher, Gustav, additional, Meunier, Lucy, additional, Goeggelmann, Pia, additional, Fianchi, Francesca, additional, Dumortier, Jérôme, additional, Riveiro-Barciela, Mar, additional, Gevers, Tom JG, additional, Beretta-Piccoli, Benedetta Terziroli, additional, Londoño, Maria-Carlota, additional, Frankova, Sona, additional, Roesner, Thomas, additional, Joerg, Vincent, additional, Schmidt, Constantin, additional, Glaser, Fabian, additional, Sutter, Jan P, additional, Fründt, Thorben W, additional, Lohse, Ansgar W, additional, Huber, Samuel, additional, von Felden, Johann, additional, Sebode, Marcial, additional, and Schulze, Kornelius, additional

Published
2023
Full Text
View/download PDF

13. Aetiology and outcome of adult and paediatric acute liver failure in Europe

Author

Lenz, Dominic, primary, Jørgensen, Marianne Hørby, additional, Kelly, Deirdre, additional, Cardinale, Vincenzo, additional, Geerts, Anja, additional, Gonçalves Costa, Isabel, additional, Fichtner, Alexander, additional, Garbade, Sven F., additional, Hegen, Bianca, additional, Hilberath, Johannes, additional, de Kleine, Ruben, additional, Kupčinskas, Limas, additional, McLin, Valérie, additional, Niesert, Moritz, additional, Prado Gonzalez, Veronica, additional, Sturm, Ekkehard, additional, Staufner, Christian, additional, Tjwa, Eric, additional, Willemse, José, additional, Zecher, Britta F., additional, Larsen, Fin Stolze, additional, Sebode, Marcial, additional, and Ytting, Henriette, additional

Published
2023
Full Text
View/download PDF

15. Importance of complete response for outcomes of pregnancy in patients with autoimmune hepatitis

Author

Fischer, Susan E., primary, de Vries, Elsemieke S., additional, Tushuizen, Maarten E., additional, de Boer, Ynto S., additional, van der Meer, Adriaan J. P., additional, de Man, Robert A., additional, Brouwer, Johannes T., additional, Kuyvenhoven, Johan P., additional, Klemt‐Kropp, Michael, additional, Gevers, Tom J. G., additional, Tjwa, Eric T. T. L., additional, Kuiper, Edith M. M., additional, Verhagen, Marc A. M. T., additional, Friederich, Philip W., additional, and van Hoek, Bart, additional

Published
2023
Full Text
View/download PDF

16. TACE-DEB vs. SBRT for hepatocellular carcinoma

Author

Romero, Alejandra Méndez, van der Holt, Bronno, Willemssen, Francois E.J.A., de Man, Rob A., Heijmen, Ben J.M., Habraken, Steven, Westerveld, Henrike, van Delden, Otto M., Klümpen, Heinz-Josef, Tjwa, Eric T.T.L., Braam, Pètra M., Jenniskens, Sjoerd F.M, Vanwolleghem, Thomas, Weytjens, Reinhilde, d'Archambeau, Olivier, de Vos-Geelen, Judith, Buijsen, Jeroen, van der Leij, Christiaan, den Toom, Wilhelm, Sprengers, Dave, Ijzermans, Jan N.M., and Moelker, Adriaan

Subjects
Human medicine
Abstract

Purpose To compare transarterial chemoembolization delivered with drug eluting beads (TACE-DEB) with stereotactioc body radiation therapy (SBRT) in patients with hepatocellular carcinoma (HCC) in a multicenter randomized trial. Materials and Methods Patients were included if they were eligible for TACE. They could also be recruited if they required treatment prior to liver transplantation. A maximum of four TACE-DEB procedures and ablation after incomplete TACE-DEB were both allowed. SBRT was delivered in six fractions of 8-9Gy. Primary end point was time to progression (TTP). Secondary endpoints were local control (LC), overall survival (OS), response rate (RR), toxicity, and quality of life (QoL). The calculated sample size was 100 patients. Results Between May 2015 and April 2020, 30 patients were randomized to the study. Due to slow accrual the trial was closed prematurely. Two patients in the SBRT arm were considered ineligible leaving 16 patients in the TACE-DEB arm and 12 in the SBRT arm. Median follow-up was 28.1 months. Median TTP was 12 months for TACE-DEB and 19 months for SBRT (p=0.15). Median LC was 12 months for TACE-DEB and >40 months (not reached) for SBRT (p=0.075). Median OS was 36.8 months for TACE-DEB and 44.1 months for SBRT (p=0.36). A post-hoc analysis showed 100% for SBRT 1- and 2-year LC, and 54.4% and 43.6% for TACE-DEB (p=0.019). Both treatments resulted in RR>80%. Three episodes of possibly related toxicity grade ≥3 were observed after TACE-DEB. No episodes were observed after SBRT. QoL remained stable after both treatment arms. Conclusions In this trial, TTP after TACE-DEB was not significantly improved by SBRT, while SBRT showed higher local antitumoral activity than TACE-DEB, without detrimental effects on OS, toxicity and QoL. To overcome poor accrual in randomized trials that include SBRT, and to generate evidence for including SBRT in treatment guidelines, international cooperation is needed.

Published
2023

18. Etiology and Outcome of Adult and Pediatric Acute Liver Failure in Europe.

Author

Lenz, Dominic, Hørby Jørgensen, Marianne, Kelly, Deirdre, Cardinale, Vincenzo, Geerts, Anja, Gonçalves Costa, Isabel, Fichtner, Alexander, Garbade, Sven F., Hegen, Bianca, Hilberath, Johannes, de Kleine, Ruben, Kupčinskas, Limas, McLin, Valérie, Niesert, Moritz, Prado Gonzalez, Veronica, Sturm, Ekkehard, Staufner, Christian, Tjwa, Eric, Willemse, José, and Zecher, Britta F.

Published
2023
Full Text
View/download PDF

25. A limited role of cytokine storm and fibrogenesis in COVID-19 related liver injury

Author

Westerouen van Meeteren, Menso J, primary, Van den Heuvel, Frederik M.A., primary, Weijers, Gert, primary, Joosten, Leo A.B., primary, De Mast, Quirijn, primary, Van de Veerdonk, Frank L., primary, Pickkers, Peter, primary, De Nooijer, Aline H., primary, Hoefsloot, Wouter, primary, Drenth, Joost P.H., primary, De Korte, Chris L., primary, Nijveldt, Robin, primary, Netea, Mihai G., primary, and Tjwa, Eric T.T.L., primary

Published
2021
Full Text
View/download PDF

28. Interleukin-1[beta] activates specific populations of enteric neurons and enteric glia in the guinea pig ileum and colon

Author

Tjwa, Eric T.T.L., Bradley, Joelle M., Keenan, Catherine M., Kroese, Alfons B.A., and Sharkey, Keith A.

Subjects
Interleukins -- Research, Biological sciences
Abstract

Fos expression was used to assess whether the proinflammatory cytokine interleukin-1[beta] (IL-1[beta]) activated specific, chemically coded neuronal populations in isolated preparations of guinea pig ileum and colon. Whether the effects of IL-1[beta] were mediated through a prostaglandin pathway and whether IL-1[beta] induced the expression of cyclooxygenase (COX)-2 was also examined. Single- and double-labeling immunohistochemistry was used after treatment of isolated tissues with IL-1[beta] (0.1-10 ng/ml). IL-1[beta] induced Fos expression in enteric neurons and also in enteric glia in the ileum and colon. For enteric neurons, activation was concentration-dependent and sensitive to indomethacin, in both the myenteric and submucosal plexuses in both regions of the gut. The maximum proportion of activated neurons differed between the ileal (~15%) and colonic (~42%) myenteric and ileal (~60%) and colonic (~75%) submucosal plexuses. The majority of neurons activated in the myenteric plexus of the ileum expressed nitric oxide synthase (NOS) or enkephalin immunoreactivity. In the colon, activated myenteric neurons expressed NOS. In the submucosal plexus of both regions of the gut, the majority of activated neurons were vasoactive intestinal polypeptide (VIP) immunoreactive. After treatment with IL-1[beta], COX-2 immunoreactivity was detected in the wall of the gut in both neurons and nonneuronal cells. In conclusion, we have found that the proinflammatory cytokine IL-1[beta] specifically activates certain neurochemically defined neural pathways and that these changes may lead to disturbances in motility observed in the inflamed bowel. myenteric plexus; submucosal plexus; cyclooxygenase-2; vasoactive intestinal polypeptide; nitric oxide synthase

Published
2003

29. Trends in incidence, diagnosis, treatment and survival of hepatocellular carcinoma in a low-incidence country: Data from the Netherlands in the period 2009–2016

Author

Reinders, Margot T.M., primary, van Meer, Suzanne, additional, Burgmans, Mark C., additional, de Jong, Koert P., additional, Klümpen, Heinz-Josef, additional, de Man, Robert A., additional, Ramsoekh, D. (Sandjai), additional, Sprengers, Dave, additional, Tjwa, Eric T.T.L., additional, de Vos-Geelen, Judith, additional, van Erpecum, Karel J., additional, and van der Geest, Lydia G.M., additional

Published
2020
Full Text
View/download PDF

33. Additional file 5: of Increased proteinase 3 and neutrophil elastase plasma concentrations are associated with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes

Author

Andreea-Manuela Mirea, Toonen, Erik, Munckhof, Inge, Munsterman, Isabelle, Tjwa, Eric, Jaeger, Martin, Oosting, Marije, Schraa, Kiki, Rutten, Joost, Graaf, Marinette, Riksen, Niels, Graaf, Jacqueline, Netea, Mihai, Tack, Cees, Chavakis, Triantafyllos, and Joosten, Leo

Abstract

Table S3. Natural logarithm transformed data for NAFLD stages analysis. (DOCX 12 kb)

Published
2019
Full Text
View/download PDF

34. Additional file 1: of Increased proteinase 3 and neutrophil elastase plasma concentrations are associated with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes

Author

Andreea-Manuela Mirea, Toonen, Erik, Munckhof, Inge, Munsterman, Isabelle, Tjwa, Eric, Jaeger, Martin, Oosting, Marije, Schraa, Kiki, Rutten, Joost, Graaf, Marinette, Riksen, Niels, Graaf, Jacqueline, Netea, Mihai, Tack, Cees, Chavakis, Triantafyllos, and Joosten, Leo

Subjects
cardiovascular diseases
Abstract

Figure S1. PR3 concentrations measured in plasma samples versus serum samples. (PPTX 65 kb)

Published
2019
Full Text
View/download PDF

36. Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study

Author

Baiges, Anna, Turon, Fanny, Simon-Talero, Macarena, Tasayco, Stephanie, Bueno, Javier, Zekrini, Kamal, Plessier, Aurelie, Franchi-Abella, Stephanie, Guerin, Florent, Mukund, Amar, Eapen, CE, Goel, Ashish, Shyamkumar, Nidugala Keshava, Coenen, Sandra, De Gottardi, Andrea, Majumdar, Avik, Onali, Simona, Shukla, Akash, Jose Carrilho, Flair, Nacif, Lucas, Primignani, Massimo, Tosetti, Giulia, La Mura, Vicenzo, Nevens, Frederik, Witters, Peter, Tripathi, Dhiraj, Tellez, Luis, Martinez, Javier, Alvarez-Navascues, Carmen, Fraile Lopez, Miguel Lopez, Procopet, Bogdan, Piscaglia, Fabio, de Koning, Barbara, Llop, Elba, Romero-Cristobal, Mario, Tjwa, Eric, Monescillo-Francia, Alberto, Senzolo, Marco, Perez-LaFuente, Mercedes, Segarra, Antonio, Sarin, Shiv Kumar, Hernandez-Gea, Virginia, Patch, David, Laleman, Wim, Hartog, Hermien, Valla, Dominique, Genesca, Joan, Carlos Garcia-Pagan, Juan, Garcia-Criado, Angeles, Darnell, Anna, Belmonte, Ernest, Ferrusquia-Acosta, Jose, Magaz, Marta, Vidal-Gonzalez, Judit, Horia, Stefanescu, Nicoara-Farcau, Oana, Joseph, Philip, Zachariah, Uday, Moses, Vinu, Mammen, Suraj, Ahmed, Munawwar, Koshy, George, Eapen, Anu, Sajith, KG, Vyas, FL, Raju, RS, Rymbai, Manbha L, Arulkumar, S, Ramachandran, Jeyamani, Elias, Elwyn, Baiges A., Turon F., Simon-Talero M., Tasayco S., Bueno J., Zekrini K., Plessier A., Franchi-Abella S., Guerin F., Mukund A., Eapen C.E., Goel A., Shyamkumar N.K., Coenen S., De Gottardi A., Majumdar A., Onali S., Shukla A., Carrilho F.J., Nacif L., Primignani M., Tosetti G., La Mura V., Nevens F., Witters P., Tripathi D., Tellez L., Martinez J., Alvarez-Navascues C., Fraile Lopez M.L., Procopet B., Piscaglia F., de Koning B., Llop E., Romero-Cristobal M., Tjwa E., Monescillo-Francia A., Senzolo M., Perez-LaFuente M., Segarra A., Sarin S.K., Hernandez-Gea V., Patch D., Laleman W., Hartog H., Valla D., Genesca J., Garcia-Pagan J.C., Gastroenterology & Hepatology, Pediatrics, and Surgery

Subjects
0301 basic medicine, Male, Vascular Malformations, medicine.medical_treatment, International Cooperation, Liver transplantation, 0302 clinical medicine, Malalties hereditàries, Hepatopulmonary syndrome, 610 Medicine & health, Child, Hepatic encephalopathy, Portal Vein, Malalties del fetge, Liver Neoplasms, vascular diseases of the liver, Middle Aged, Abernethy, Child, Preschool, 030211 gastroenterology & hepatology, Female, medicine.symptom, Genetic diseases, Adult, medicine.medical_specialty, Adenoma, Adolescent, Hypertension, Pulmonary, Asymptomatic, 03 medical and health sciences, Young Adult, extrahepatic portosytemic shunt, medicine, Humans, Liver diseases, Aged, Retrospective Studies, Abernethy Malformation, Hepatology, business.industry, Infant, Retrospective cohort study, medicine.disease, Pulmonary hypertension, Surgery, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], 030104 developmental biology, Hepatic Encephalopathy, Congenital malformation, Portosystemic shunt, business, Hepatopulmonary Syndrome
Abstract

Contains fulltext : 220051.pdf (Publisher’s version ) (Closed access) Congenital extrahepatic portosystemic shunt (CEPS) or Abernethy malformation is a rare condition in which splanchnic venous blood bypasses the liver draining directly into systemic circulation through a congenital shunt. Patients may develop hepatic encephalopathy (HE), pulmonary hypertension (PaHT), or liver tumors, among other complications. However, the actual incidence of such complications is unknown, mainly because of the lack of a protocolized approach to these patients. This study characterizes the clinical manifestations and outcome of a large cohort of CEPS patients with the aim of proposing a guide for their management. This is an observational, multicenter, international study. Sixty-six patients were included; median age at the end of follow-up was 30 years. Nineteen patients (28%) presented HE. Ten-, 20-, and 30-year HE incidence rates were 13%, 24%, and 28%, respectively. No clinical factors predicted HE. Twenty-five patients had benign nodular lesions. Ten patients developed adenomas (median age, 18 years), and another 8 developed HCC (median age, 39 years). Of 10 patients with dyspnea, PaHT was diagnosed in 8 and hepatopulmonary syndrome in 2. Pulmonary complications were only screened for in 19 asymptomatic patients, and PaHT was identified in 2. Six patients underwent liver transplantation for hepatocellular carcinoma or adenoma. Shunt closure was performed in 15 patients with improvement/stability/cure of CEPS manifestations. Conclusion: CEPS patients may develop severe complications. Screening for asymptomatic complications and close surveillance is needed. Shunt closure should be considered both as a therapeutic and prophylactic approach.

Published
2018

37. Nationwide treatment and outcomes of perihilar cholangiocarcinoma.

Author

Keulen, Anne‐Marleen, Franssen, Stijn, Geest, Lydia G., Boer, Marieke T., Coenraad, Minneke, Driel, Lydi M. J. W., Erdmann, Joris I., Haj Mohammad, Nadia, Heij, Lara, Klümpen, Heinz‐Josef, Tjwa, Eric, Valkenburg‐van Iersel, Liselot, Verheij, Joanne, Groot Koerkamp, Bas, and Olthof, Pim B.

Subjects
OVERALL survival, SURVIVAL rate, TREATMENT effectiveness, CHOLANGIOCARCINOMA, DIAGNOSIS
Abstract

Background: Perihilar cholangiocarcinoma (pCCA) is a rare tumour that requires complex multidisciplinary management. All known data are almost exclusively derived from expert centres. This study aimed to analyse the outcomes of patients with pCCA in a nationwide cohort. Methods: Data on all patients diagnosed with pCCA in the Netherlands between 2010 and 2018 were obtained from the Netherlands Cancer Registry. Data included type of hospital of diagnosis and the received treatment. Outcomes included the type of treatment and overall survival. Results: A total of 2031 patients were included and the median overall survival for the overall cohort was 5.2 (95% CI 4.7‐5.7) months. Three‐hundred‐ten (15%) patients underwent surgical resection, 271 (13%) underwent palliative systemic treatment, 21 (1%) palliative local anti‐cancer treatment and 1429 (70%) underwent best supportive care. These treatments resulted in a median overall survival of 29.6 (95% CI 25.2‐34.0), 12.2 (95% CI 11.0‐13.3), 14.5 (95%CI 8.2‐20.8) and 2.9 (95% CI 2.6‐3.2) months respectively. Resection rate was 13% in patients who were diagnosed in non‐academic and 32% in academic centres (P <.001), which resulted in a survival difference in favour of academic centres. Median overall survival was 9.7 (95% CI 7.7‐11.7) months in academic centres compared to 4.9 (95% CI 4.3‐5.4) months in non‐academic centres (P <.001). Conclusions: In patients with pCCA, resection rate and overall survival were higher for patients who were diagnosed in academic centres. These results show population‐based outcomes of pCCA and highlight the importance of regional collaboration in the treatment of these patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

41. Increased proteinase 3 and neutrophil elastase plasma concentrations are associated with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes

Author

Mirea, Andreea-Manuela, primary, Toonen, Erik J. M., additional, van den Munckhof, Inge, additional, Munsterman, Isabelle D., additional, Tjwa, Eric T. T. L., additional, Jaeger, Martin, additional, Oosting, Marije, additional, Schraa, Kiki, additional, Rutten, Joost H. W., additional, van der Graaf, Marinette, additional, Riksen, Niels P., additional, de Graaf, Jacqueline, additional, Netea, Mihai G., additional, Tack, Cees J., additional, Chavakis, Triantafyllos, additional, and Joosten, Leo A. B., additional

Published
2019
Full Text
View/download PDF

44. PREVALENCE AND FACTORS ASSOCIATED WITH NAFLD IN PEOPLE WITH HIV.

Author

van Eekeren, Louise E., Blaauw, Marc J. T., Vadaq, Nadira, Matzaraki, Vasiliki, Vos, Wilhelm A. J. W., Groenendijk, Albert L., Navas, Adriana, Weijers, Gert, van Der Kolk, Mike, van Der Ven, Andre J. A. M., De Mast, Quirijn, Joosten, Leo, and Tjwa, Eric

Published
2023

45. Management of ruptured hepatocellular carcinoma in a European tertiary care center

Author

Rijckborst, Vincent, ter Borg, MJ, Tjwa, Eric, Sprengers, Dave, Verhoef, Kees, Moelker, Adriaan, IJzermans, J.N.M., de Man, Rob, Gastroenterology & Hepatology, Surgery, and Radiology & Nuclear Medicine

Abstract

Goals and background Spontaneous rupture is a rare complication of hepatocellular carcinoma (HCC). Treatment options consist of transcatheter arterial embolization (TAE), hepatic resection, and conservative therapy. The best approach is under debate. Study This study presents a review of clinical data of patients with a ruptured HCC admitted to a European tertiary care center. Results Eleven patients were included; six (55%) had underlying cirrhosis. The majority of patients (73%) had no previous history of HCC. Spontaneous HCC rupture was diagnosed using abdominal computed tomography with or without a diagnostic paracentesis. Computed tomography showed one or two tumors in eight (73%) patients; the other patients had multiple tumors or diffuse infiltrative HCC. Seven (64%) patients were initially treated by TAE and one (9%) patient underwent hepatic resection. The remaining three (27%) patients, all of whom had liver cirrhosis, received conservative therapy. Two patients initially treated by TAE underwent a delayed resection and ultimately received systemic therapy. Overall, at the end of the follow`-up period, three patients were still alive at 84, 991, and 1026 days after the initial presentation. Eight (73%) patients had died after a median of 88 days (range 7-417). One year after presentation, none of the conservatively treated patients was alive compared with three out of seven (43%) patients treated with TAE with or without delayed resection. Conclusion Patients with a spontaneously ruptured HCC have a poor prognosis. In selected patients, however, prolonged survival is possible using TAE as initial therapy with or without a delayed resection and systemic therapy. Eur J Gastroenterol Hepatol 28:963-966 Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results